All News

Experts sparred over the feasibility and appropriateness of using minimal residual disease (MRD) to determine the duration of first-line CLL treatment.

ACA cancellations rise; HBV re-engagement varies by outreach; rural US has 44% fewer clinicians; diabetes and alopecia need custom care.

The conference, set to take place in Baltimore, Maryland, will feature 4 days of sessions focusing on sleep medicine and how it affects overall health.

Final results of the CLL14 study reveal the efficacy of 1-year venetoclax-obinutuzumab therapy for chronic lymphocytic leukemia.

Organized screening in Hong Kong narrowed socioeconomic disparities over 9 years, although suboptimal uptake persists in key groups.

Longer patient survival times require a shift toward earlier surrogate end points, with measurable residual disease (MRD) providing robust evidence of its utility for accelerating access to myeloma treatment.

Distrust, misinformation, and conflict complicate Ebola response efforts in the DRC, highlighting broader challenges to public health trust.

ADA 2026 spotlighted triple incretin therapy, intensive LDL lowering, and the equity gaps that keep advances from reaching all patients.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

New evidence links oxidative stress to vitiligo autoimmunity, highlighting antioxidant plus phototherapy or JAK combinations for better repigmentation.

The CHG index predicted CKM syndrome onset, progression, and adverse outcomes, suggesting a simple tool for risk stratification across disease stages.

Pharmacy deserts affect 1 in 7 Americans, and hospital-owned specialty pharmacies can help close the gap in medication access.

As GLP-1 approvals expand into new indications, claims data reveal most treated patients already qualify under multiple indications.

The use of in-hospital statins in older adults admitted to an acute geriatric ward was associated with in-hospital mortality.

Forging multistakeholder partnerships and prioritizing high-impact specialities can help convert market volatility to an advantage.

Sandra Chaparro, MD, discusses using obesity medications in patients with heart failure.

Shields Health Solutions is collaborating with Baptist Health to launch an integrated onsite specialty pharmacy at Baptist MD Anderson Cancer Center.

The FDA approved a supplemental BLA for Organon's tocilizumab biosimilar Tofidence.

A review finds diet, micronutrients, aerobic exercise, and mental health screening complement psoriasis treatment, lowering severity and comorbidity risk.

CHMP issued a positive opinion for nerandomilast in IPF and PPF, bringing the therapy closer to European Union approval.

MS was not linked to worse cardiovascular surgery outcomes, though routine home discharge was lower in this population.

In patients with NSCLC, 3+1 lymph node sampling was not linked to higher postoperative complications, supporting guideline adherence.

At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.

State data reveal 2026 ACA marketplace enrollment losses are accelerating post open enrollment, as cancellations surge and affordability pressures mount after tax credits expired.

The treatment worked in patients with generalized myasthenia gravis (gMG) regardless of previous immunosuppressive treatment or concomitant use of other gMG treatments.

Sandra Chaparro, MD, makes the case for SGLT2 inhibitors across a broad spectrum of chronic kidney disease, even in patients without diabetes.

Alopecia areata shapes how people work, learn, and see themselves, a new occupational review finds, with barriers reaching far beyond hair loss.

Rural America has 44% fewer health care workers per capita than urban areas, with psychologists and physicians hit hardest.